Advertisement

Health-Related Quality of Life in Patients with Immune Thrombocytopenia

  • Robert J. Klaassen
  • Nancy L. Young
Chapter

Abstract

I walked into the examination room to see my second patient of the day—five other families were quietly sitting in the waiting room awaiting their turn. She was a 15-year-old girl with immune thrombocytopenia (ITP) diagnosed just over 1 year ago. Her platelet count ranged from 20 to 30 × 109/l, but she had not required any emergency department visits or had any significant bleeding events over the past 6 months. All in all she seemed stable, so my plan was to continue with the current treatment approach of “watch and wait”.

References

  1. Barnard D, Woloski M, Feeny D, McCusker P, Wu J, David M, Bussel J, Lusher J, Wakefield C, Henriques S, Blanchette V. Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol. 2003;25(1):56–62.CrossRefPubMedGoogle Scholar
  2. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47.CrossRefPubMedGoogle Scholar
  3. Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315–25.CrossRefPubMedGoogle Scholar
  4. Calman KC. Quality of life in cancer patients—an hypothesis. J Med Ethics. 1984;10(3):124–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hematol. 2016;91(10):995–1001.CrossRefPubMedGoogle Scholar
  6. Eiser C, Jenney M. Measuring quality of life. Arch Dis Child. 2007;92(4):348–50.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Flores A, Klaassen RJ, Buchanan GR, Neunert CE. Patterns and influences in health-related quality of life in children with immune thrombocytopenia: a study from the Dallas ITP Cohort. Pediatr Blood Cancer. 2017;64(8):e26405.CrossRefGoogle Scholar
  8. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409–15.CrossRefPubMedGoogle Scholar
  9. Grace R, Despotovic J, Bennett C, Klaassen RJ. Fatigue in pediatric immune thrombocytopenia (ITP): baseline prevalence in patients starting second line therapies in the first ITP consortium of North America research study (ICON1). Pediatr Blood Cancer. 2016;63(S1):S20. Ref Type: Abstract.Google Scholar
  10. Grainger JD, Young NL, Blanchette VS, Klaassen RJ. Quality of life in immune thrombocytopenia following treatment. Arch Dis Child. 2013;98(11):895–7.CrossRefPubMedGoogle Scholar
  11. Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual Life Res. 2009;18(1):115–23.CrossRefPubMedGoogle Scholar
  12. Heitink-Polle KM, Haverman L, Annink KV, Schep SJ, de HM, Bruin MC. Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica. 2014;99(9):1525–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol. 2015;170(2):141–9.CrossRefPubMedGoogle Scholar
  14. Klaassen RJ, Blanchette V, Burke TA, Wakefield C, Grainger JD, Gaedicke G, Riedlinger A, Dufort G, Citrin E, Reguerre Y, Pellier I, Curtis C, Young NL. Quality of life in childhood immune thrombocytopenia: international validation of the kids’ ITP tools. Pediatr Blood Cancer. 2013;60(1):95–100.CrossRefPubMedGoogle Scholar
  15. Klaassen RJ, Blanchette VS, Barnard D, Wakefield CD, Curtis C, Bradley CS, Neufeld EJ, Buchanan GR, Silva MP, Chan AK, Young NL. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the kids’ ITP tools. J Pediatr. 2007;150(5):510–5.CrossRefPubMedGoogle Scholar
  16. Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2011;58(3):395–8.CrossRefPubMedGoogle Scholar
  17. Klaassen RJ, Young NL. Health-related quality of life outcomes for patients with immune thrombocytopenic purpura. Ann Hematol. 2010;89(1):51–4.CrossRefPubMedGoogle Scholar
  18. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–99.CrossRefPubMedGoogle Scholar
  19. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007;5:11.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Mathias SD, Gao SK, Rutstein M, Snyder CF, Wu AW, Cella D. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin. 2009;25(2):375–83.CrossRefPubMedGoogle Scholar
  21. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150–4.CrossRefPubMedGoogle Scholar
  22. Mokhtar GM, Farid SM, Shaker NM, Farrag KE. Health-related quality of life of Egyptian children with immune thrombocytopenia and their parents. J Pediatr Hematol Oncol. 2014;36(3):194–9.CrossRefPubMedGoogle Scholar
  23. Neunert CE, Buchanan GR, Blanchette V, Barnard D, Young NL, Curtis C, Klaassen RJ. Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura. Pediatr Blood Cancer. 2009;53(4):652–4.CrossRefPubMedGoogle Scholar
  24. Newton JL, Reese JA, Watson SI, Vesely SK, Bolton-Maggs PH, George JN, Terrell DR. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011;86(5):420–9.CrossRefPubMedGoogle Scholar
  25. Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14(1):90–6.CrossRefPubMedGoogle Scholar
  26. Snyder CF, Mathias SD, Cella D, Isitt JJ, Wu AW, Young J. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med ResOpin. 2008;24(10):2767–76.CrossRefGoogle Scholar
  27. Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45–54.CrossRefPubMedGoogle Scholar
  28. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329–41.CrossRefPubMedGoogle Scholar
  29. Ware JE. SF-36 health survey update. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcome assessment, vol. 3. 3rd ed. Mahwah: Lawrence Erlbaum Associates; 2004. p. 693–718.Google Scholar
  30. WHOQOL Group. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res. 1993;2(2):153–9.CrossRefGoogle Scholar
  31. Zhou Z, Yang L, Chen Z, Chen X, Guo Y, Wang X, Dong X, Wang T, Zhang L, Qiu Z, Yang R. Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. Eur J Haematol. 2007;78(6):518–23.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of PediatricsUniversity of Ottawa, Children’s Hospital of Eastern OntarioOttawaCanada
  2. 2.School of Rural and Northern Health, Laurentian UniversitySudburyCanada

Personalised recommendations